-
BioBlock
New!
Nasal spray with antibodies against SARS-CoV-2, which helps to prevent the spread of the virus. -
Profemina intimate cream
(available soon)
Probiotic cream for women health. Lactobacillus crispatus
-
Profemina probiotic capsules
(available soon)
Probiotic capsules for women health. Lactobacillus crispatus
Research and Patent
Research and Patent
A USPTO patent application (No. 63/160,833) has been submitted by the product developers.
Our published paper in scientific journal PLOS ONE
BioBlock antibody efficiency on Delta and Omicron
Colostrum immunoglobulin preparation blocks SARS-CoV-2 Spike protein binding to ACE2 receptor in ELISA assay
BioBlock antibody solution blocks SARS-CoV-2 virus entry into animal cells
In collaboration with Tartu University scientists, we tested BioBlock antibodies’ ability to block SARS-CoV-2 virus entry into Vero E6 cells
Results demonstrate that BioBlock antibodies are capable of blocking virus entry into the cells at concentration of 20 mg/ml
BioBlock nasal spray contains antibodies at concentration of 0,2 mg/ml
Immunoglobulins from immunized cows inhibit SARS-CoV-2 virus entry to Vero E6 cells in the cytopathic effect neutralization assay
Colostrum derived immunoglobulins from immunized cows neutralize pseudovirus displaying different Spike proteins of currently circulating SARS-CoV-2 variantsvariants
BioBlock antibody solution reduces the SARS-CoV-2 viral load found in Syrian Golden Hamsters lungs
Syrian Golden Hamsters (n=8) were administered BioBlock intranasally at two different concentrations (0.1 mg/mL and 0.2 mg/mL), followed by an infection of SARS-CoV-2 virus (105 pfu). After 4 days the lung viral titer was determined. BioBlock antibody solution reduces viral load even after a single intranasal administering dose.
Antibodies in Bioblock remain on the human nasal mucosa at least 4 hours after administration
Clinical Trial Assessing the Efficacy and Safety of BioBlock®
Randomized, Controlled, Double-Blind Proof of Concept Trial Assessing the Efficacy and Safety of BioBlock® Intranasally Administered Virus-Neutralizing Bovine Colostrum Nasal Spray in Preventing of COVID-19 Infection in Healthy Volunteer Individuals.
This is a randomized (1: 1) parallel study of a double-blind cluster of proof of concept. The randomization unit is healthy volunteers who have no symptoms of COVID-19 at baseline and have not been infected with SARS-CoV-2 for the past 90 days. Selected subjects are be randomly assigned to either an experimental group (subjects using BioBlock® Antiviral Nasal Spray immediately after waking up in the morning and once every 4 hours thereafter for 28 days) or a control group (subjects using placebo immediately after waking up in the morning and once every 4 hours thereafter and so within 28 days).
For both study groups, a rapid COVID-19 antigen test is scheduled twice weekly or for 4 consecutive weeks if symptoms of COVID-19 infection occur.
Cases of side effects are recorded during the study.
Indicative duration of the study is March 2022-August 2022
